FR3097741B1 - Bactérie du genre Massiliomicrobiota et composition en contenant pour son utilisation comme médicament - Google Patents

Bactérie du genre Massiliomicrobiota et composition en contenant pour son utilisation comme médicament Download PDF

Info

Publication number
FR3097741B1
FR3097741B1 FR1906844A FR1906844A FR3097741B1 FR 3097741 B1 FR3097741 B1 FR 3097741B1 FR 1906844 A FR1906844 A FR 1906844A FR 1906844 A FR1906844 A FR 1906844A FR 3097741 B1 FR3097741 B1 FR 3097741B1
Authority
FR
France
Prior art keywords
massiliomicrobiota
genus
bacteria
medicament
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1906844A
Other languages
English (en)
Other versions
FR3097741A1 (fr
Inventor
Georges Rawadi
Sandrine Claus
Laure Rinaldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VERB BIOTICS, US
Original Assignee
Lnc Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lnc Therapeutics filed Critical Lnc Therapeutics
Priority to FR1906844A priority Critical patent/FR3097741B1/fr
Publication of FR3097741A1 publication Critical patent/FR3097741A1/fr
Application granted granted Critical
Publication of FR3097741B1 publication Critical patent/FR3097741B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’invention concerne l’utilisation de bactéries du genre Massiliomicrobiota ou de compositions en contenant comme médicaments chez l’être humain ou l’animal
FR1906844A 2019-06-25 2019-06-25 Bactérie du genre Massiliomicrobiota et composition en contenant pour son utilisation comme médicament Active FR3097741B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1906844A FR3097741B1 (fr) 2019-06-25 2019-06-25 Bactérie du genre Massiliomicrobiota et composition en contenant pour son utilisation comme médicament

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1906844A FR3097741B1 (fr) 2019-06-25 2019-06-25 Bactérie du genre Massiliomicrobiota et composition en contenant pour son utilisation comme médicament
FR1906844 2019-06-25

Publications (2)

Publication Number Publication Date
FR3097741A1 FR3097741A1 (fr) 2021-01-01
FR3097741B1 true FR3097741B1 (fr) 2021-06-25

Family

ID=68138454

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1906844A Active FR3097741B1 (fr) 2019-06-25 2019-06-25 Bactérie du genre Massiliomicrobiota et composition en contenant pour son utilisation comme médicament

Country Status (1)

Country Link
FR (1) FR3097741B1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119639884A (zh) * 2024-12-17 2025-03-18 成都市第三人民医院 一种用于评估内脏型肥胖的微生物标志物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008064489A1 (fr) * 2006-12-01 2008-06-05 Mcmaster University Probiotiques destinés à inhiber les inflammations

Also Published As

Publication number Publication date
FR3097741A1 (fr) 2021-01-01

Similar Documents

Publication Publication Date Title
EP3924481A4 (fr) Compositions et méthodes de traitement d'hémoglobinopathies
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
EP4276114A3 (fr) Anticorps à domaine unique ciblant cd20
WO2019032662A8 (fr) Agents de liaison à clec9a et utilisations associées
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
MA33295B1 (fr) Nouvelle formulation de diclofénac
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
BRPI0515446A (pt) amidas bicìclicas como inibidores de cinases
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
DE602004014170D1 (de) Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit
IL281809A (en) Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
MX2022013736A (es) Composiciones protectoras de herbicidas que contienen amidas de acido n-(1,3,4-oxadiazol-2-il)arilcarboxilico.
WO2018232275A3 (fr) Traitement antimicrobien de carcasses d'animaux et de produits alimentaires
EP3791869A4 (fr) Composition pharmaceutique de prévention ou de traitement de maladies neurodégénératives comprenant l'agent d'acétylation cox2 comme ingrédient actif
FR3076997B1 (fr) Extrait obtenu a partir de plusieurs plantes pour son utilisation dans la prevention et/ou le traitement des maladies chroniques inflammatoires de l'intestin
EP4329753A4 (fr) Compositions pharmaceutiques et systèmes d'administration intravitréenne de médicament pour le traitement de maladies oculaires
MA29453B1 (fr) Associations synergiques de medicaments anti-inflammatoires non steroidiens avec des ligands d'alpha-2-delta
EP3866786A4 (fr) Compositions et procédés de suppression et/ou de traitement de maladies métaboliques et/ou d'une affection clinique associée
FR3097741B1 (fr) Bactérie du genre Massiliomicrobiota et composition en contenant pour son utilisation comme médicament
EP3946277A4 (fr) Compositions pharmaceutiques orodispersibles d'apixaban
EP4070786A4 (fr) Composition pharmaceutique contenant de l'élémène, son procédé de préparation et son utilisation
MX2020010243A (es) Composiciones bucales y metodos para animales.
FR3065009B1 (fr) Secretome bacterien pour son utilisation dans le traitement des lesions cutanees
EP4007610A4 (fr) Compositions et méthodes de traitement d' alpha-thalassémie

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210101

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

TP Transmission of property

Owner name: VERB BIOTICS, US

Effective date: 20231123

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7